Evidence map›Paper›PMID 35611804›Full record

ArticleJournal of cellular and molecular medicine2022

Notch3 expression in capillary pericytes predicts worse graft outcome in human renal grafts with antibody-mediated rejection.

Yichun Xu-Dubois, Panagiotis Kavvadas, Zela Keuylian, Alexandre Hertig, Eric Rondeau, Christos Chatziantoniou

Abstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yichun Xu-DuboisINSERM UMRS 1155, Tenon Hospital, Paris, France.
Panagiotis KavvadasINSERM UMRS 1155, Tenon Hospital, Paris, France.
Zela KeuylianINSERM UMRS 1155, Tenon Hospital, Paris, France.
Alexandre HertigINSERM UMRS 1155, Tenon Hospital, Paris, France.
Eric RondeauINSERM UMRS 1155, Tenon Hospital, Paris, France.
Christos ChatziantoniouINSERM UMRS 1155, Tenon Hospital, Paris, France.ORCID 0000-0003-4440-099X

Funding

Agence Nationale de la RechercheInstitut National de la Santé et de la Recherche MédicaleSorbonne Université
6 · The paper itself

Abstract

Microvasculature consisting of endothelial cells and pericytes is the main site of injury during antibody-mediated rejection (ABMR) of renal grafts. Little is known about the mechanisms of activation of pericytes in this pathology. We have found recently that activation of Notch3, a mediator of vascular smooth muscle cell proliferation and dedifferentiation, promotes renal inflammation and fibrosis and aggravates progression of renal disease. Therefore, we studied the pericyte expression of Notch3 in 49 non-selected renal graft biopsies (32 for clinical cause, 17 for graft surveillance). We analysed its relationship with patients' clinical and morphological data, and compared with the expression of partial endothelial mesenchymal transition (pEndMT) markers, known to reflect endothelial activation during ABMR. Notch3 was de novo expressed in pericytes of grafts with ABMR, and was significantly correlated with the microcirculation inflammation scores of peritubular capillaritis and glomerulitis and with the expression of pEndMT markers. Notch3 expression was also associated with graft dysfunction and proteinuria at the time of biopsy and in the long term. Multivariate analysis confirmed pericyte expression of Notch3 as an independent risk factor predicting graft loss. These data suggest that Notch3 is activated in the pericytes of renal grafts with ABMR and is associated with poor graft outcome.

Indexed as

Graft RejectionPericytesReceptor, Notch3AntibodiesBiomarkersBiopsyEndothelial CellsHumansInflammationAntibodiesBiomarkersNOTCH3 protein, humanReceptor, Notch3antibody-mediated graft rejectionkidneyNotch3pericytes

Identifiers

PMID35611804
PMCPMC9170800

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.